background : coronary artery diseases are one of the causes of early death all over the world. in developed countries, ischemic heart disease is responsible for the half of the entire mortalities; however in developing countries it is estimated from 9 million deaths per year annually 32 percent of all deaths due to coronary artery disease. acute coronary syndromes are responsible for over 250,0...

The purpose of this communication is to review briefly the agents available at the present time for use in thrombolytic therapy and to indicate why we believe that at the present time streptokinase is the only suitable agent for extended clinical trial. An account will then be given of the use of streptokinase administered by local perfusion in the treatment of peripheral arterial occlusion and...

Thrombolytic therapy, also known as clot busting drug, is a breakthrough treatment which has saved untold lives. It has been used in the clinical area to treat venous and arterial thromboembolic complaints which are a foremost cause of death. In 1761, Morgagni lead the way of thrombolytic therapy. Now day's different types of thrombolytic drugs are currently available in market: alteplase, anis...

Background: Thrombolytic therapy in patients with sub-massive pulmonary embolism (SMPTE) needs further assessment. Objectives: The current study aimed to assess a potential benefit of thrombolytic and non-thrombolytic therapy in patients with SMPTE. Patients andMethods: One hundred-nineteen patients were enrolled with SMPTE from 2006 to 2010 in the tertiary care center of Rajaie medical and res...

BACKGROUND National guidelines have encouraged increased use of thrombolytic therapy for elderly patients with acute myocardial infarction (AMI). However, evidence supporting thrombolytic therapy in patients 75 years and older is lacking. In a retrospective cohort study of 2659 elderly AMI patients, we determined the association between thrombolytic use and in-hospital mortality by age and amon...

PURPOSE To determine whether subclinical cholesterol embolization is a frequent sequela of thrombolytic therapy. Case reports of catastrophic cholesterol embolization temporally associated with thrombolytic therapy in 19 patients have suggested a causal relationship. PATIENTS AND METHODS We prospectively followed 60 patients with acute myocardial infarction who underwent coronary bypass surge...

Objectives: To compare a system of prehospital thrombolytic therapy, delivered by paramedics under medical guidance, with in-hospital thrombolytic therapy in meeting National Service Framework (NSF) targets for treatment of acute myocardial infarction at a District General Hospital setting in England. Design: Retrospective observational case-control study comparing patients with suspected acute...

or benefit from this approach. We searched for studies including two or more patients treated with throm¬ bolytic agents. Ten studies were reviewed. We de¬ scribe and include two patients with valve thrombosis treated at our institution. A total of 182 episodes of prosthetic valve thrombosis in 162 patients were ex¬ amined. Clinical success was achieved in 72.0% of cases and there was a mortali...

BACKGROUND QT dispersion (QTd) is equal to longer QTc minus shorter QTc measured by 12-lead electrocardiogram (ECG). QTd reflects inhomogeneity in repolarization of ventricular myocardium and because of easy and fast measurement of QTd, it can be used to predict high-risk patients for dysrhythmia after Acute Myocardial Infarction (AMI). OBJECTIVES This study aimed to assess the effect of thro...